Ticker brief
RARE
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
28
authors 14d
19
crowd 14d
-1.3σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-19 → 2026-08-28 · now +0.20 (−1 bearish … +1 bullish)
Who spoke19
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 4 | +0.49 |
| @BiopharmIQ | B | · | 4 | +0.38 |
| @Briefingcom | B | +0.50 | 2 | +0.35 |
| @cnfinancewatch | B | -1.92 | 2 | +0.25 |
| @ClassicRoy | C | -1.52 | 2 | -0.05 |
| @MartyChargin | C | -0.27 | 1 | +0.50 |
| @HammerstoneMar3 | C | +0.39 | 1 | +0.50 |
| @EmmanuelInvest | C | -1.11 | 1 | +0.50 |
| @AlertsAndNews | C | -1.90 | 1 | +0.50 |
| @WallStDiaries | C | -0.20 | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @CAGThe3rd | C | -1.73 | 1 | +0.80 |
| @HejToJeMara | B | -1.43 | 1 | -0.50 |
| @JoshTradeOption | C | -0.75 | 1 | +0.75 |
| @BPharmCatalyst | C | · | 1 | +0.00 |
| @shanaka86 | A | +1.96 | 1 | -0.80 |
| @TeresaTrades | C | · | 1 | +0.10 |
| @cfaryanoconnell | C | -1.48 | 1 | -0.20 |
| @Quantumup1 | C | · | 1 | +0.40 |
Recent signals28of 28 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @BiopharmIQ | +0.00 | Explains CELU's 139% move and lists upcoming biotech regulatory catalysts | · | tweet ↗ |
| 2026-08-28 | @Quantumup1 | +0.40 | Wells Fargo raises RARE's target to $50 from $46 and maintains Overweight. | · | tweet ↗ |
| 2026-08-27 | @cfaryanoconnell | -0.20 | The author lists the first six stocks with increasing unusual put-option volume. | · | tweet ↗ |
| 2026-08-27 | @ClassicRoy | -0.15 | Lists stocks with increasing unusual put-option volume. | · | tweet ↗ |
| 2026-08-27 | @ClassicRoy | +0.05 | Lists the largest decreases in put open interest. | · | tweet ↗ |
| 2026-08-27 | @TeresaTrades | +0.10 | Lists the largest decreases in put open interest. | · | tweet ↗ |
| 2026-08-25 | @semodough | +0.55 | Relays Baird's positive bias into Aspire Phase 3 data and a potential $1B-plus product opportunity. | · | tweet ↗ |
| 2026-08-24 | @shanaka86 | -0.80 | Detailed critique argues Genglycos approval relies on reduced protective therapy despite increased hypoglycemia exposure. | · | tweet ↗ |
| 2026-08-23 | @cnfinancewatch | +0.35 | Ranks six favored stocks using institutional ownership, insider buying, analyst actions and catalysts. | · | tweet ↗ |
| 2026-08-23 | @cnfinancewatch | +0.15 | Lists dated FDA approvals and upcoming PDUFA decisions across a biotech catalyst basket. | · | tweet ↗ |
| 2026-08-21 | @semodough | +0.40 | Morgan Stanley gives RARE a $74 target and $101 bull case while reviewing approval and catalysts. | · | tweet ↗ |
| 2026-08-21 | @BPharmCatalyst | +0.00 | Weekly watchlist highlights biotech names with remaining quarterly PDUFA catalysts. | · | tweet ↗ |
| 2026-08-20 | @JoshTradeOption | +0.75 | Sell 12 Oct 2026 $17.50 puts to fund one Jan 2028 $10 call. — Proposes a concrete bullish multi-leg RARE options trade with strikes, expiries, and premiums. | · | tweet ↗ |
| 2026-08-20 | @HejToJeMara | -0.50 | Author harshly criticizes five biotechs, emphasizing IMUX's 12.5x share-count dilution. | · | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | +0.50 | FDA granted accelerated approval to Ultragenyx's first gene therapy, with launch expected in 30-60 days. | · | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | +0.50 | Biotech opening roundup lists FDA, clinical-data, approval and offering catalysts with associated price moves. | · | tweet ↗ |
| 2026-08-20 | @CAGThe3rd | +0.80 | Discloses an existing leveraged RARE long and a bullish compression thesis. | · | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | +0.50 | FDA accelerated approval removes a key regulatory risk for RARE's first approved gene therapy. | · | tweet ↗ |
| 2026-08-20 | @OpenOutcrier | +0.50 | Ultragenyx won its first FDA approval for a gene therapy treating a rare metabolic disorder. | · | tweet ↗ |
| 2026-08-20 | @Briefingcom | +0.50 | Ultragenyx received FDA accelerated approval for GENGLYCOS in GSDIa. | · | tweet ↗ |
| 2026-08-20 | @Briefingcom | +0.20 | Lists leading premarket gaps, capped at the first six tickers under the extraction limit. | · | tweet ↗ |
| 2026-08-20 | @WallStDiaries | +0.50 | FDA approved RARE's first gene therapy, sending shares up 6% after hours. | · | tweet ↗ |
| 2026-08-19 | @AlertsAndNews | +0.50 | FDA approved Ultragenyx's GENGLYCOS gene therapy, the first treatment addressing GSDIa's cause. | · | tweet ↗ |
| 2026-08-19 | @semodough | +0.50 | Cantor raised RARE's target to $103 after accelerated FDA approval of GENGLYCOS. | · | tweet ↗ |
| 2026-08-19 | @semodough | +0.50 | Ultragenyx announced FDA approval of GENGLYCOS, the first treatment targeting GSDIa's underlying cause. | · | tweet ↗ |
| 2026-08-19 | @EmmanuelInvest | +0.50 | Reports accelerated FDA approval for Ultragenyx's GENGLYCOS gene therapy. | · | tweet ↗ |
| 2026-08-19 | @HammerstoneMar3 | +0.50 | Reports FDA approval of Ultragenyx's GENGLYCOS gene therapy. | · | tweet ↗ |
| 2026-08-19 | @MartyChargin | +0.50 | FDA granted accelerated approval for GENGLYCOS in GSDIa. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.